MediWound

MediWound Ltd. is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. | Nasdaq: $MDWD

[MediWound @MediWound]

$MDWD MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®

Read the full press release here: https://t.co/RYYYyOT4f5

[MediWound @MediWound]

$MDWD Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification

Read the full press release here: https://t.co/AngM9nOjWK

[MediWound @MediWound]

$MDWD MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Read the full press release here: https://t.co/NhFQW9cw1J

[MediWound @MediWound]

$MDWD MediWound to Report Second Quarter 2026 Financial Results

Read the full press release here: https://t.co/DY4QPkKQ72

[MediWound @MediWound]

$MDWD MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

Read the full press release here: https://t.co/u4evjjvj9D

[MediWound @MediWound]

$MDWD MediWound to Report First Quarter 2026 Financial Results

Read the full press release here: https://t.co/vFhoq6P96D

[MediWound @MediWound]

$MDWD Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement

Read the full press release here: https://t.co/pChBfksV3C

[MediWound @MediWound]

$MDWD MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

Read the full press release here: https://t.co/ajX6FKEe8i

[MediWound @MediWound]

$MDWD MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

Read the full press release here: https://t.co/5W7d06Tfck

[MediWound @MediWound]

$MDWD MediWound Files Annual Report on Form 20-F

Read the full press release here: https://t.co/HyS7dur43n

[MediWound @MediWound]

$MDWD MediWound Reports Fourth Quarter and Full Year 2025 Financial Results

Read the full press release here: https://t.co/gcLRE6sVkj

[MediWound @MediWound]

$MDWD MediWound to Report Fourth Quarter and Full Year 2025 Financial Results

Read the full press release here: https://t.co/zTh3uscyXi

[MediWound @MediWound]

$MDWD MediWound to Present at Upcoming Investor Conferences

Read the full press release here: https://t.co/dvi9WI1EE6

[MediWound @MediWound]

$MDWD MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference

Read the full press release here: https://t.co/2OPcbqAd9C

[MediWound @MediWound]

$MDWD MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries

Read the full press release here: https://t.co/9ofRxjG7fQ

[MediWound @MediWound]

$MDWD MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Read the full press release here: https://t.co/PHkaRBjvqd

[MediWound @MediWound]

$MDWD MediWound to Report Third Quarter 2025 Financial Results

Read the full press release here: https://t.co/boOuPidJga

[MediWound @MediWound]

$MDWD MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®

Read the full press release here: https://t.co/6H0X7CHFjN